Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura
Clinical trial NCT05468320 · COMPLETED
Trial details
- NCT number
- NCT05468320
- Sponsor
- Sanofi
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-21
- Primary completion
- 2024-12-26
- Enrollment
- 51
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.